|
EP1575916B1
(en)
|
2001-08-31 |
2013-05-22 |
The Rockefeller University |
Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
|
|
EP1444009A1
(en)
*
|
2001-11-02 |
2004-08-11 |
Pfizer Products Inc. |
Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
|
|
US20030195205A1
(en)
*
|
2001-11-02 |
2003-10-16 |
Pfizer Inc. |
PDE9 inhibitors for treating cardiovascular disorders
|
|
US7262187B2
(en)
|
2001-12-06 |
2007-08-28 |
Merck & Co., Inc. |
Substituted oxazolo- and thizaolopyrimidinones as a mitotic kinesin inhibitor
|
|
JP2005516968A
(ja)
*
|
2001-12-29 |
2005-06-09 |
ノボ ノルディスク アクティーゼルスカブ |
Ｇｌｐ−１化合物と糖尿病後期合併症モジュレーターの組み合わせ使用
|
|
IS1935B
(is)
*
|
2002-03-19 |
2004-06-16 |
Actavis Group Hf. |
Fósínópríl lyfjasamsetning
|
|
ATE478872T1
(de)
*
|
2002-03-28 |
2010-09-15 |
Ustav Ex Botan Av Cr V V I I O |
Pyrazoloä4,3-düpyrimidine, verfahren zu ihrer herstellung und therapeutische anwendung
|
|
DE10238723A1
(de)
*
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
|
DE10238722A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
|
|
DE10238724A1
(de)
*
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
|
US20040220186A1
(en)
*
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
|
DE10320785A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Arylmethyl-substituierte Pyrazolopyrimidine
|
|
DE102004004142A1
(de)
*
|
2003-05-09 |
2004-11-25 |
Bayer Healthcare Ag |
6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
|
|
CA2524900C
(en)
*
|
2003-05-09 |
2012-03-20 |
Bayer Healthcare Ag |
6-cyclylmethyl- and 6-alkylmethyl-substituted pyrazolopyrimidines
|
|
US8044060B2
(en)
|
2003-05-09 |
2011-10-25 |
Boehringer Ingelheim International Gmbh |
6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory
|
|
WO2005041972A1
(en)
*
|
2003-10-31 |
2005-05-12 |
Pfizer Products Inc. |
Phosphodiesterase 9 inhibition as treatment for obesity-related conditions
|
|
US20080125403A1
(en)
|
2004-04-02 |
2008-05-29 |
Merck & Co., Inc. |
Method of Treating Men with Metabolic and Anthropometric Disorders
|
|
US7531556B2
(en)
*
|
2004-04-28 |
2009-05-12 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
CN1960735B
(zh)
*
|
2004-05-20 |
2015-07-29 |
代阿麦迪卡股份有限公司 |
药物组合在治疗胰岛素抗性中的应用
|
|
WO2006135080A1
(ja)
|
2005-06-14 |
2006-12-21 |
Aska Pharmaceutical Co., Ltd. |
チエノピリミジン誘導体
|
|
EP1919287A4
(en)
*
|
2005-08-23 |
2010-04-28 |
Intra Cellular Therapies Inc |
ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
|
|
AU2007282678B2
(en)
*
|
2006-08-08 |
2012-09-27 |
Aska Pharmaceutical Co., Ltd. |
Quinazoline derivative
|
|
JP2010502670A
(ja)
|
2006-09-07 |
2010-01-28 |
ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング |
真性糖尿病のための組合せ治療
|
|
AU2007299920A1
(en)
*
|
2006-09-19 |
2008-03-27 |
Braincells, Inc. |
PPAR Mediated Modulation of Neurogenesis
|
|
CA2671980C
(en)
|
2006-12-13 |
2015-05-05 |
Aska Pharmaceutical Co., Ltd. |
Quinoxaline derivatives
|
|
WO2008072778A1
(ja)
*
|
2006-12-13 |
2008-06-19 |
Aska Pharmaceutical Co., Ltd. |
尿路系疾患の処置剤
|
|
ITMI20070140A1
(it)
*
|
2007-01-30 |
2008-07-31 |
Campagnolo Srl |
Dispositivo di interazione uomo-bicicletta
|
|
US20100144864A1
(en)
*
|
2007-04-05 |
2010-06-10 |
Ironwood Pharmaceuticals, Inc. |
Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
|
|
PT2152712E
(pt)
*
|
2007-05-11 |
2012-02-29 |
Pfizer |
Compostos amino-heterocíclicos
|
|
ES2465216T3
(es)
|
2007-06-04 |
2014-06-05 |
Ben Gurion University Of The Negev Research And Development Authority |
Compuestos de triarilo y composiciones que comprenden los mismos
|
|
JP5498392B2
(ja)
*
|
2007-11-30 |
2014-05-21 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
１，５−ジヒドロ−ピラゾロ［３，４−ｄ］ピリミジン−４−オン誘導体及びｃｎｓ障害の治療のためのｐｄｅ９ａモジュレーターとしてのそれらの使用
|
|
KR20100121527A
(ko)
|
2008-02-29 |
2010-11-17 |
콘서트 파마슈티컬즈, 인크. |
치환된 잔틴 유도체
|
|
UA105362C2
(en)
|
2008-04-02 |
2014-05-12 |
Бьорингер Ингельхайм Интернациональ Гмбх |
1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
|
|
JP5453431B2
(ja)
|
2008-09-08 |
2014-03-26 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
|
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
|
JP5557845B2
(ja)
|
2008-10-31 |
2014-07-23 |
メルク・シャープ・アンド・ドーム・コーポレーション |
糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
|
|
TWI404721B
(zh)
|
2009-01-26 |
2013-08-11 |
Pfizer |
胺基－雜環化合物
|
|
US20110053961A1
(en)
|
2009-02-27 |
2011-03-03 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
|
PE20120505A1
(es)
|
2009-03-31 |
2012-05-09 |
Boehringer Ingelheim Int |
Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
|
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
|
AR078793A1
(es)
|
2009-10-27 |
2011-12-07 |
Orion Corp |
Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
|
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
|
AP2012006631A0
(en)
|
2010-08-12 |
2012-12-31 |
Boehringer Ingelheim Int |
6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
|
|
RS54834B1
(sr)
|
2010-09-07 |
2016-10-31 |
Astellas Pharma Inc |
Jedinjenja pirazolokvinolina
|
|
RU2603140C2
(ru)
*
|
2010-09-20 |
2016-11-20 |
Айронвуд Фармасьютикалз, Инк. |
Соединения имидазотриазинона
|
|
US8809345B2
(en)
|
2011-02-15 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders
|
|
BR112013021236B1
(pt)
|
2011-02-25 |
2021-05-25 |
Merck Sharp & Dohme Corp |
composto derivado de benzimidazol, e, composição
|
|
WO2013013052A1
(en)
|
2011-07-19 |
2013-01-24 |
Concert Pharmaceuticals, Inc. |
Substituted xanthine derivatives
|
|
SG11201502728WA
(en)
|
2011-10-10 |
2015-05-28 |
Lundbeck & Co As H |
Pde9i with imidazo pyrazinone backbone
|
|
BR112014018199A8
(pt)
*
|
2012-01-26 |
2021-03-02 |
H Lundbeck As |
inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação
|
|
EP2828262A4
(en)
|
2012-03-19 |
2015-09-23 |
Forum Pharmaceuticals Inc |
IMIDAZOTRIAZINONVERBINDUNGEN
|
|
US20130315891A1
(en)
|
2012-05-25 |
2013-11-28 |
Matthew Charles |
Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
|
|
EP2854841B1
(en)
|
2012-06-04 |
2017-02-22 |
Diamedica Inc. |
Human tissue kallikrein 1 glycosylation isoforms
|
|
US9527875B2
(en)
|
2012-08-02 |
2016-12-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CN102786525B
(zh)
|
2012-08-08 |
2014-12-17 |
中山大学 |
N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用
|
|
WO2014024125A1
(en)
|
2012-08-08 |
2014-02-13 |
Celon Pharma S.A. |
Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
|
|
RU2015140066A
(ru)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
Противодиабетические бициклические соединения
|
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
|
JP2015067538A
(ja)
*
|
2013-09-26 |
2015-04-13 |
株式会社アイエイアイ |
血糖値降下剤
|
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
|
CR20160207A
(es)
|
2013-11-05 |
2016-08-10 |
Ben Gurion Univ Of The Negev Res And Dev Authority |
Compuestos para el tratamiento de la diabetes y las complicaciones que surgen de la misma enfermedad
|
|
US20170216296A1
(en)
|
2014-04-18 |
2017-08-03 |
Concert Pharmaceuticals, Inc. |
Methods of treating hyperglycemia
|
|
HRP20240082T1
(hr)
|
2015-07-07 |
2024-03-29 |
H. Lundbeck A/S |
Inhibitor pde9 s okosnicom imidazopirazinona za liječenje perifernih bolesti
|
|
TW201811799A
(zh)
|
2016-09-09 |
2018-04-01 |
美商英塞特公司 |
吡唑并嘧啶化合物及其用途
|
|
WO2018049214A1
(en)
|
2016-09-09 |
2018-03-15 |
Incyte Corporation |
Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
|
|
UA125650C2
(uk)
|
2016-09-09 |
2022-05-11 |
Інсайт Корпорейшн |
Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку
|
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
|
US20180228786A1
(en)
|
2017-02-15 |
2018-08-16 |
Incyte Corporation |
Pyrazolopyridine compounds and uses thereof
|
|
CN110446501A
(zh)
|
2017-03-09 |
2019-11-12 |
代阿麦迪卡股份有限公司 |
组织激肽释放酶1的剂型
|
|
DK3630772T3
(da)
*
|
2017-05-26 |
2024-02-05 |
Cardurion Pharmaceuticals Inc |
Fremgangsmåder til fremstilling og anvendelse af pde9-hæmmere
|
|
RU2019144010A
(ru)
|
2017-06-08 |
2021-07-13 |
Мерк Шарп И Доум Корп. |
Пиразолопиримидиновые ингибиторы pde9
|
|
US10722495B2
(en)
|
2017-09-08 |
2020-07-28 |
Incyte Corporation |
Cyanoindazole compounds and uses thereof
|
|
WO2019164847A1
(en)
|
2018-02-20 |
2019-08-29 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US10800761B2
(en)
|
2018-02-20 |
2020-10-13 |
Incyte Corporation |
Carboxamide compounds and uses thereof
|
|
US10745388B2
(en)
|
2018-02-20 |
2020-08-18 |
Incyte Corporation |
Indazole compounds and uses thereof
|
|
US11299473B2
(en)
|
2018-04-13 |
2022-04-12 |
Incyte Corporation |
Benzimidazole and indole compounds and uses thereof
|
|
FI3801526T3
(fi)
|
2018-05-25 |
2024-03-20 |
Cardurion Pharmaceuticals Inc |
6-[(3s,4s)-4-metyyli-1-(pyrimidin-2-yylimetyyli)pyrrolidin-3-yyli]-3-tetrahydropyran-4-yyli-7h-imidatso[1,5-a]pyratsin-8-onin monohydraattimuotoja ja kiteisiä muotoja
|
|
US10899755B2
(en)
|
2018-08-08 |
2021-01-26 |
Incyte Corporation |
Benzothiazole compounds and uses thereof
|
|
EP3843737A4
(en)
|
2018-08-31 |
2022-06-01 |
Imara Inc. |
PDE9 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE
|
|
ES2973117T3
(es)
|
2018-09-25 |
2024-06-18 |
Incyte Corp |
Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR
|
|
MX2022001562A
(es)
|
2019-08-06 |
2022-04-26 |
Incyte Corp |
Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1).
|
|
AU2021370658A1
(en)
*
|
2020-10-27 |
2023-06-08 |
Cardurion Pharmaceuticals, Inc. |
Pde9 inhibitors for treating cardiac failure
|